EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (CLAUDE)
A Phase 2 Trial of EO2040, a miCrobiaL-derived Peptide therApeUtic Vaccine, in Combination With Nivolumab, for Treatment of Patients With ctDNA-dEfined Minimal Residual Disease of CRC Stage II, III, or IV After Curative Therapy
Sponsor: Enterome
Terminated
the study recruitment is significantly behind expectations as only one single patient has started treatment
Other terminated trials from Enterome
- Colorectal Cancer Metastatic · Phase PHASE1/PHASE2 · May 2025
- Adrenocortical Carcinoma · Phase PHASE1/PHASE2 · Oct 2024
- Crohn's Disease · Phase NA · Dec 2017
More terminations from Enterome
Other Colorectal Cancer trials with similar outcome
A PHASE2 clinical study on Colorectal Cancer, this trial is terminated or withdrawn. The trial is conducted by Enterome and has accumulated 12 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2
-
Jul 2025 — Oct 2025 [monthly]
Terminated PHASE2
-
Jan 2025 — Jul 2025 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Aug 2023 — Apr 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Enterome
For direct contact, visit the study record on ClinicalTrials.gov .